CORRECTION

Correction to: Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease

Emma E. Wolters[1,2] · Rik Ossenkoppele[2,3] · Sander C. J. Verfaillie[1] · Emma M. Coomans[1] · Tessa Timmers[1,2] · Denise Visser[1,2] · Hayel Tuncel[1] · Sandeep S. V. Golla[1] · Albert D. Windhorst[1] · Ronald Boellaard[1] · Wiesje M. van der Flier[2,4] · Charlotte E. Teunissen[5] · Philip Scheltens[2] · Bart N. M. van Berckel[1]

Correction to: Eur J Nucl Med Mol Imaging
https://doi.org/10.1007/s00259-020-04758-2

The authors regret to inform readers that the following error was detected in the original article. The values for entorhinal, limbic and neortical SUVr were switched between SCD Aβ + and Aβ- in Table 1 and have now been corrected. Unnecessary symbols in Table 2 have been removed.

This article is part of the Topical Collection on Erratum.

The online version of the original article can be found at https://doi.org/10.1007/s00259-020-04758-2

✉ Emma E. Wolters
   ee.wolters@amsterdamumc.nl

1   Department of Radiology and Nuclear Medicine, Amsterdam, Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

2   Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

3   Clinical Memory Research Unit, Lund University, Lund, Sweden

4   Department of Epidemiology and Biostatistics, Vrije Universiteit, Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

5   Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

Table 1 Demographic, clinical and AD biomarker characteristics over the total sample and per disease group

	SCD Aβ+ (n = 10)	SCD Aβ- (n = 15)	MCI/AD (n = 53)	Total Sample (n = 78)	Total SCD (n = 25)
Age, years	67 ± 6	64 ± 6	65 ± 7	65 ± 7	65 ± 6
Female, %	60%	60%	53%	43%	60%
No. Aß positive subjects	10(100%)	0(0%)	53 (100%)	63 (81%)	10 (40%)
Education, Verhage scale, median(range)	6 (4–7)	6 (2–7)	6 (3–7)	6 (2–7)	6 (2–7)
Time lag LP/PET, years	0.7 ± 0.6	0.9 ± 0.5	0.6 ± 0.5	0.7 ± 0.5	0.8 ± 0.7
Neuropsychological measures					
MMSE (n = 78)	28 ± 1	28 ± 1	23 ± 4[b]	25 ± 4	28 ± 1
Memory[c] (n = 78)	−0.5 ± 0.8	0.3 ± 0.6	−3.1 ± 2.1[b]	−2.1 ± 2.3	−0.0 ± 0.8
Attention[d] (n = 73)	−0.2 ± 0.6	0.1 ± 0.6	−1.3 ± 1.2[b]	−0.9 ± 1.2	−0.0 ± 0.6
Language[e] (n = 68)	−0.0 ± 0.4	0.0 ± 0.8	−1.0 ± 1.0[b]	−0.6 ± 1.0	−0.0 ± 0.7
Executive functioning[f] (n = 73)	−0.1 ± 0.9	−0.1 ± 0.7	−2.4 ± 1.0[b]	−0.9 ± 1.1	0.0 ± 0.8
Tau biomarkers					
CSF					
CSF Aß$_{1-42}$	779 ± 197	1067 ± 217	541 ± 113[b]	677 ± 260	966 ± 247
CSF t-tau	615 ± 383	257 ± 201	760 ± 412[b]	645 ± 422	401 ± 333
CSF p-tau	83 ± 36	43 ± 23	90 ± 35[b]	80 ± 38	59 ± 38
[^{18}F]flortaucipir PET					
Entorhinal cortex BP$_{ND}$	0.2 ± 0.2	−0.1 ± 0.1	0.3 ± 0.2[b]	0.2 ± 0.2	−0.0 ± 0.2
Limbic region BP$_{ND}$	0.2 ± 0.1	0.0 ± 0.0	0.4 ± 0.2[b]	0.3 ± 0.2	0.1 ± 0.1
Neocortex BP$_{ND}$	0.1 ± 0.1	−0.0 ± 0.0	0.3 ± 0.3[b]	0.2 ± 0.3	0.0 ± 0.1
Entorhinal cortex SUVr	1.3 ± 0.2	1.0 ± 0.1	1.5 ± 0.2[b]	1.4 ± 0.3	1.1 ± 0.2
Limbic region SUVr	1.3 ± 0.2	1.1 ± 0.1	1.5 ± 0.2[b]	1.4 ± 0.3	1.2 ± 0.1
Neocortex SUVr	1.2 ± 0.2	1.1 ± 0.1	1.4 ± 0.3[b]	1.3 ± 0.3	1.1 ± 0.1

Continuous data shown as mean ± standard deviation, unless specified otherwise. Differences in demographic, clinical and AD biomarker characteristics between disease groups were assessed using ANOVA for continuous variables and χ^2 for dichotomous data. [a] Significantly different from SCD subjects at $p < 0.05$. [b] Significantly different from SCD subjects at $p < 0.01$ [c] Z-score Memory domain, [d] Z-score Attention domain, [e] Z-score Language domain, [f] Z-score Executive functioning domain

Table 2 Standardized ß coefficients for the relationship between CSF p-tau and entorhinal, limbic and neocortical [^{18}F]flortaucipir BP$_{ND}$ or SUVr over the total sample and stratified per disease group

	Total Sample (n = 78) CSF p-tau	SCD (n = 25) CSF p-tau	MCI/AD (n = 53) CSF p-tau
Entorhinal [^{18}F]flortaucipir BP$_{ND}$	**0.46**($p < 0.01$)	0.43($p = 0.07$)	0.17($p = 0.17$)
Limbic [^{18}F]flortaucipir BP$_{ND}$	**0.45**($p < 0.01$)	**0.59**($p = 0.01$)	0.22($p = 0.08$)
Neocortical [^{18}F]flortaucipir BP$_{ND}$	**0.43**($p < 0.01$)	**0.54**($p = 0.02$)	**0.27**($p = 0.03$)
Entorhinal [^{18}F]flortaucipir SUVr	**0.50**($p < 0.01$))	**0.59**($p < 0.01$)	0.16($p = 0.21$)
Limbic [^{18}F]flortaucipir SUVr	**0.47**($p < 0.01$)	**0.67**($p < 0.01$)	0.21($p = 0.09$)
Neocortical [^{18}F]flortaucipir SUVr	**0.43**($p < 0.01$)	0.41($p = 0.08$)	**0.26**($p = 0.03$)

Standardized ß coefficients (significant in bold) from regression analysis with [^{18}F]flortaucipir BP$_{ND}$ or SUVr as the dependent variables and CSF p-tau as predictor

Effects adjusted for age, sex and time lag between LP and [^{18}F]flortaucipir PET